Intravesical Mitomycin C After Diagnostic Ureteroscopy for Upper Tract Urothelial Carcinoma
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorMcMaster University
About this trial
The objective of this pilot study is to determine the feasibility of conducting a phase III randomized trial of intravesical mitomycin C (MMC) for prevention of intravesical recurrence (IVR) after diagnostic ureteroscopy for suspected upper tract urothelial carcinoma (UTUC). In the current study, 40 patients will be randomized to receive MMC or no intervention and will be followed for two years to determine the incidence of adverse events and IVR.
Eligibility criteria
Qualifiers
Suspected upper tract urothelial carcinoma (UTUC)
Diagnostic ureteroscopy required
Tumor suggestive of upper tract urothelial carcinoma (UTUC) found on ureteroscopy
Disqualifiers
Prior or concomitant urothelial carcinoma of the bladder
History of UTUC
Ureteroscopy within the preceding six months
Untreated urinary tract infection
Trial design
Treatments tested in this trial
- Mitomycin C
Treatment groups
40 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov